Usually, it is considered that an increased tumor TIDE score is associated with a worse ICB response, as well as a lower likelihood of survival under anti-PD1 and anti-CTLA4 therapy (Jiang et al., 2018; Zhang et al., 2021). This evidence concerns the gene CTLA4 and neoplasm.